Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05629429 | Olaparib Maintenance Therapy in Metastatic Breast Cancer | unknown | Phase 2 | 300 | National Taiwan University HospitalOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04398524 |
| A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC |
| unknown |
| Phase 2 |
| 65 |
| ISA PharmaceuticalsINDUSTRY |
| 9 |
| Jan 16, 2024 |
| clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04617457 | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas(HOLIPANC) | unknown | Phase 2 | 150 | University of CologneOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06201507 | BV-AVD-R Treatment Children Hodgkin's Lymphoma | unknown | Phase 2 | 44 | Beijing Children's HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05296278 | Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC | unknown | Phase 2 | 70 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05296603 | Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 83 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06198465 | Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | unknown | Phase 2 | 24 | Xijing HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06197438 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05590221 | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma | unknown | Phase 2 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06195683 | Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.(NSCLC) | unknown | Phase 2 | 23 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04197492 | Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | unknown | Phase 2 | 22 | Huashan HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE(CELEBRATE) | unknown | Phase 1 / Phase 2 | 78 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01541709 | Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI | unknown | Phase 2 | 23 | Asan Medical CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04589754 | Adriamycin and Ifosfamide Combined With Sintilimab | unknown | Phase 2 | 176 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05859477 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer(NIVOFGFR2) | unknown | Phase 2 | 23 | Kidney Cancer Research BureauOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT03807102 | Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer(TVATLC01) | unknown | Phase 1 / Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04715217 | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 24 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04937972 | SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma(FLYFLY) | unknown | Phase 2 | 71 | Hunan Province Tumor HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05611879 | Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | unknown | Phase 2 | 30 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT02098954 | Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers | unknown | Phase 2 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03646968 | Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study(SAVE) | unknown | Phase 2 | 43 | Yongchang ZhangOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06104553 | A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182800 | Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy | unknown | Phase 2 | 35 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT03256981 | Stereotactic Body Radiotherapy for the Treatment of OPD(HALT) | unknown | Phase 2 / Phase 3 | 113 | Institute of Cancer Research, United KingdomOTHER | 5 | Dec 26, 2023 | clinicaltrials |
| NCT05820191 | B-amyloid as a Marker for GBM Bioimaging | unknown | Phase 2 | 3 | Universidad Central del CaribeOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06178601 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 36 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04329429 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | unknown | Phase 2 | 57 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06170697 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05757466 | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma(Prolgo-HL) | unknown | Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02969083 | Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma(URANUS) | unknown | Phase 2 | 200 | The European Uro-Oncology GroupOTHER | 3 | Dec 18, 2023 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03935256 | Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer | unknown | Phase 2 | 24 | Loyola UniversityOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC(ANZUP2001) | unknown | Phase 2 | 93 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 17, 2024source: clinicaltrials